Replimune Net Worth
Replimune Net Worth Breakdown | REPL |
Replimune Net Worth Analysis
Replimune's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Replimune's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Replimune's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Replimune's net worth analysis. One common approach is to calculate Replimune's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Replimune's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Replimune's net worth. This approach calculates the present value of Replimune's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Replimune's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Replimune's net worth. This involves comparing Replimune's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Replimune's net worth relative to its peers.
Enterprise Value |
|
To determine if Replimune is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Replimune's net worth research are outlined below:
| Replimune Group generated a negative expected return over the last 90 days | |
| Replimune Group has high historical volatility and very poor performance | |
| Net Loss for the year was (215.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Replimune Group currently holds about 395.08 M in cash with (185.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.01. | |
| Replimune Group has a frail financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Replimune Group Stock Price Up 6.4 percent Whats Next |
Replimune uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Replimune Group. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Replimune's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 16th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 16th of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Replimune Target Price Consensus
Replimune target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Replimune's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Strong Buy |
Most Replimune analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Replimune stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Replimune Group, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationReplimune Target Price Projection
Replimune's current and average target prices are 11.50 and 18.38, respectively. The current price of Replimune is the price at which Replimune Group is currently trading. On the other hand, Replimune's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Replimune Target Price
Know Replimune's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Replimune is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Replimune Group backward and forwards among themselves. Replimune's institutional investor refers to the entity that pools money to purchase Replimune's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Boxer Capital Management, Llc | 2024-12-31 | 1.8 M | Boxer Capital Llc | 2024-09-30 | 1.5 M | Braidwell Lp | 2024-12-31 | 1.5 M | Geode Capital Management, Llc | 2024-12-31 | 1.4 M | Millennium Management Llc | 2024-12-31 | 1.2 M | Wellington Management Company Llp | 2024-12-31 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1 M | D. E. Shaw & Co Lp | 2024-12-31 | 972.6 K | Mpm Oncology Impact Management Lp | 2024-12-31 | 950 K | Baker Bros Advisors Lp | 2024-12-31 | 11 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 11 M |
Follow Replimune's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 907.23 M.Market Cap |
|
Project Replimune's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.51) | (0.53) | |
| Return On Capital Employed | (0.60) | (0.63) | |
| Return On Assets | (0.51) | (0.53) | |
| Return On Equity | (0.66) | (0.63) |
When accessing Replimune's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Replimune's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Replimune's profitability and make more informed investment decisions.
Evaluate Replimune's management efficiency
Replimune Group has return on total asset (ROA) of (0.263) % which means that it has lost $0.263 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.505) %, meaning that it created substantial loss on money invested by shareholders. Replimune's management efficiency ratios could be used to measure how well Replimune manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.53. The value of Return On Capital Employed is expected to slide to -0.63. At this time, Replimune's Net Tangible Assets are quite stable compared to the past year. Other Current Assets is expected to rise to about 9.8 M this year, although the value of Total Assets will most likely fall to about 359.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.06 | 4.37 | |
| Tangible Book Value Per Share | 5.06 | 4.37 | |
| Enterprise Value Over EBITDA | (2.02) | (2.12) | |
| Price Book Value Ratio | 1.24 | 1.30 | |
| Enterprise Value Multiple | (2.02) | (2.12) | |
| Price Fair Value | 1.24 | 1.30 | |
| Enterprise Value | 464.4 M | 527.2 M |
Effective leadership at Replimune drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Replimune insiders, such as employees or executives, is commonly permitted as long as it does not rely on Replimune's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Replimune insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Replimune Corporate Filings
| 14th of March 2025 Other Reports | ViewVerify | |
8K | 7th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 18th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Replimune Earnings Estimation Breakdown
The calculation of Replimune's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Replimune is estimated to be -0.7032 with the future projection ranging from a low of -0.7475 to a high of -0.6625. Please be aware that this consensus of annual earnings estimates for Replimune Group is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.75 Lowest | Expected EPS | -0.66 Highest |
Replimune Earnings Projection Consensus
Suppose the current estimates of Replimune's value are higher than the current market price of the Replimune stock. In this case, investors may conclude that Replimune is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Replimune's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 8 | 89.61% | -0.79 | -0.7032 | -3.07 |
Replimune Earnings per Share Projection vs Actual
Actual Earning per Share of Replimune refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Replimune Group predict the company's earnings will be in the future. The higher the earnings per share of Replimune, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Replimune Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Replimune, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Replimune should always be considered in relation to other companies to make a more educated investment decision.Replimune Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Replimune's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-06 | 2024-12-31 | -0.72 | -0.79 | -0.07 | 9 | ||
2024-11-05 | 2024-09-30 | -0.77 | -0.6753 | 0.0947 | 12 | ||
2024-08-08 | 2024-06-30 | -0.85 | -0.78 | 0.07 | 8 | ||
2024-05-16 | 2024-03-31 | -0.79 | -0.82 | -0.03 | 3 | ||
2024-02-08 | 2023-12-31 | -0.93 | -0.77 | 0.16 | 17 | ||
2023-11-07 | 2023-09-30 | -0.86 | -0.9 | -0.04 | 4 | ||
2023-08-03 | 2023-06-30 | -0.84 | -0.75 | 0.09 | 10 | ||
2023-05-18 | 2023-03-31 | -0.67 | -0.74 | -0.07 | 10 | ||
2023-02-09 | 2022-12-31 | -0.75 | -0.69 | 0.06 | 8 | ||
2022-11-03 | 2022-09-30 | -0.78 | -0.79 | -0.01 | 1 | ||
2022-08-04 | 2022-06-30 | -0.64 | -0.78 | -0.14 | 21 | ||
2022-05-19 | 2022-03-31 | -0.58 | -0.6 | -0.02 | 3 | ||
2022-02-03 | 2021-12-31 | -0.58 | -0.57 | 0.01 | 1 | ||
2021-11-04 | 2021-09-30 | -0.54 | -0.56 | -0.02 | 3 | ||
2021-08-06 | 2021-06-30 | -0.46 | -0.53 | -0.07 | 15 | ||
2021-05-20 | 2021-03-31 | -0.41 | -0.41 | 0.0 | 0 | ||
2021-02-04 | 2020-12-31 | -0.42 | -0.42 | 0.0 | 0 | ||
2020-11-05 | 2020-09-30 | -0.44 | -0.46 | -0.02 | 4 | ||
2020-08-07 | 2020-06-30 | -0.46 | -0.44 | 0.02 | 4 | ||
2020-06-03 | 2020-03-31 | -0.45 | -0.41 | 0.04 | 8 | ||
2020-02-13 | 2019-12-31 | -0.36 | -0.46 | -0.1 | 27 | ||
2019-11-11 | 2019-09-30 | -0.35 | -0.35 | 0.0 | 0 | ||
2019-08-14 | 2019-06-30 | -0.32 | -0.3 | 0.02 | 6 | ||
2019-06-28 | 2019-03-31 | -0.4 | -0.15 | 0.25 | 62 | ||
2019-02-14 | 2018-12-31 | -0.24 | -0.24 | 0.0 | 0 | ||
2018-11-14 | 2018-09-30 | -0.2 | -0.26 | -0.06 | 30 | ||
2018-08-30 | 2018-06-30 | -0.23 | -2.02 | -1.79 | 778 | ||
2018-04-11 | 2018-03-31 | 0 | -0.42 | -0.42 | 0 |
Replimune Corporate Management
| Colin Love | Chief Officer | Profile | |
| Christopher Sarchi | Chief Officer | Profile | |
| Carolyn Trott | Senior Assurance | Profile | |
| Pamela Esposito | Chief Business Officer | Profile | |
| Paul Bullock | Chief Head | Profile | |
| MBA MA | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.